BioVersys AG a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, announced today that its preclinical candidate BV100 has received Qualified Infectious Disease Product designation from the U.S. FDA for intravenous use in the treatment of ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP) and bloodstream infections (BSI).
BV100, a narrow spectrum compound with exceptional in vitro and in vivo antimicrobial activity on Acinetobacter baumannii is being developed initially for the treatment of multidrug-, extensively drug and pandrug-resistant (MDR, XDR & PDR) ventilator-associated bacterial pneumonia (VABP) and hospital-acquired bacterial pneumonia (HABP) infections.
Full PR available here